Gene expression in breast cancer

Current Treatment Options in Oncology

Volumn 7, Issue 2, 2006, Pages 123-128

  Kaklamani, Virginia G ^b   Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FATTY ACID BINDING PROTEIN; FLUOROURACIL; KERATIN; LAMININ; METHOTREXATE; PLACEBO; TAMOXIFEN;

AMPLICON; ANALYTICAL EQUIPMENT; BIOASSAY; BREAST CANCER; CANCER GENETICS; CANCER THERAPY; CLINICAL TRIAL; DNA MICROARRAY; GENE CLUSTER; GENE EXPRESSION PROFILING; HUMAN; MEDICAL DECISION MAKING; NETHERLANDS; PATIENT CARE; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RISK ASSESSMENT;

EID: 33644560320     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0047-0     Document Type: Review

References (17)

1. Early Breast Cancer Trialists' Collaborative Group (EBGTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
2. Esteban JM, Baker JB, Cronin M, et al.: Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue. Proc Am Soc Clin Oncol 2003, 22:850.
3. Fisher B, Costantino J, Redmond C, et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989, 320:479-484.
4. Perou CM, Sorlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
5. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001 98:10869-10874.
6. Paik S, Shak S, Tang G, et al.: Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients-NSABP studies B-20 and B-14. Breast Cancer Res Treat 2003, 82:A16.
7. Cronin M, Pho M, Dutta D, et al.: Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004, 164:35-42.
8. van de Vijver MJ, He YD, van't Veer LJ, et al.: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
9. Rouzier R, Anderson K, Hess KR, et al.: Basal and luminal types of breast cancer defined by gene expression patterns respond differently to neoadjuvant chemotherapy [abstract 201]. Breast Cancer Res Treat 2004, 88(Suppl 1):S24.
10. Carey LA, Dees EC, Sawyer LR, et al.: The triple negative paradox: primary tumor chemosensitivity of the basal-like breast cancer phenotype [abstract 1023]. Breast Cancer Res Treat 2004, 88(Suppl 1):S48.
11. Carey LA, Kim NW, Goodman S, et al.: Telomerase activity and prognosis in primary breast cancers. J Clin Oncol 1999, 17:3075-3081.
12. Simon R: Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer 2003, 89:1599-1604.
13. Cobleigh MA, Bitterman P, Baker JB, et al.: Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: high throughout RT-PCR assay of paraffin-embedded tumor tissues. Proc Am Soc Clin Oncol 2003, 22:850.
14. Paik S, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxiden-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
15. van't Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
16. Wang Y, Klijn JG, Zhang Y, et al.: Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. Lancet 2005, 365:671-679.
17. Foekens JA, Atkins D, Sweep CGJ, et al.: Multi-center validation of the 76-gene prognostic signature in lymph node negative primary breast cancer. Breast Cancer Res Treat 2005, 94(Suppl 1):28.